Company news

3D Medicines, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Voluntary announcement latest progress in collaboration programs: achievement of pre-specified number of events in the global pivotal phase 3 regal trial for 3D189

October 29, 2026

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026

October 6, 2026

Change of principal share registrar and transfer office

October 2, 2026

Interim Report 2026

September 30, 2026

Discloseable transaction

September 17, 2026

3D Medicines Inc Says Envafolimab Supplemental Application Accepted By NMPA

February 9, 2026

3D Medicines Inc Says Zhang Jing Resigns As CFO

January 12, 2026

3D Medicines Says New Drug Application For First-Line Treatment Of Biliary Tract Cancer Of Envafolimab Accepted

January 9, 2026

3D Medicines Says Envafoimab Granted Orphan Drug Designation

December 22, 2025

Decks